First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age | Zendy

Angelica Petrillo | Zendy; Annalisa Pappalardo | Zendy; F. Calabrese | Zendy; Giuseppe Tirino | Zendy; Luca Pompella | Zendy; Jole Ventriglia | Zendy; Maria Maddalena Laterza | Zendy; Marianna Caterino | Zendy; Vincenzo Sforza | Zendy; Vega Iranzo | Zendy; Maria Biglietto | Zendy; Michele Orditura | Zendy; Fortunato Ciardiello | Zendy; Giovanni Conzo | Zendy; Carlo Molino | Zendy; Ferdinando De Vita | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age

Author(s) -

Angelica Petrillo,

Annalisa Pappalardo,

F. Calabrese,

Giuseppe Tirino,

Luca Pompella,

Jole Ventriglia,

Maria Maddalena Laterza,

Marianna Caterino,

Vincenzo Sforza,

Vega Iranzo,

Maria Biglietto,

Michele Orditura,

Fortunato Ciardiello,

Giovanni Conzo,

Carlo Molino,

Ferdinando De Vita

Publication year - 2019

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.084

H-Index - 39

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2019.06.02

Subject(s) - medicine , gemcitabine , neutropenia , anemia , population , pancreatic cancer , adverse effect , univariate analysis , performance status , paclitaxel , oncology , surgery , gastroenterology , toxicity , cancer , multivariate analysis , environmental health

Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the elderly as first-line treatment for mPC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research